How to Help Your Patients Find Praluent in Stock: A Provider's Guide

Prescribing Praluent (alirocumab) is the straightforward part. Ensuring your patient actually receives it — on schedule and at a cost they can sustain — requires navigating specialty pharmacy logistics, insurance bureaucracy, and financial assistance programs that most patients aren't equipped to handle alone. This guide gives your practice a repeatable workflow to help patients access Praluent successfully.

Step 1: Verify Formulary Status Before You Write the Prescription

Before prescribing Praluent, check the patient's insurance formulary. Approximately 50% of commercial plans cover Praluent; the other half may prefer Repatha (evolocumab) or require step therapy through ezetimibe first. Since both PCSK9 inhibitors have comparable clinical efficacy (50–65% LDL-C reduction and ~15% relative MACE reduction in outcomes trials), prescribing the formulary-preferred agent reduces PA friction, cost, and the risk of prescription abandonment.

If your patient has a specific clinical or adherence reason to prefer Praluent's dosing schedule (75 mg q2wk vs. Repatha's 140 mg q2wk or 420 mg monthly), document that rationale — it strengthens the PA submission.

Step 2: Build a Complete Prior Authorization Packet Up Front

First-round PA approval rates for Praluent improve significantly when submissions include complete documentation from the start. Train your PA staff to include:

Primary diagnosis with ICD-10 code (ASCVD: I25.10, I63.9, Z87.39; HeFH: E78.01; HoFH: E78.00)

Current LDL-C with recent lab date (within 6 months preferred)

Documented statin therapy: drug name, dose, duration, and designation as "maximally tolerated" with rationale

Ezetimibe trial: name, dose, duration, LDL-C response or intolerance documentation

Brief prescriber statement of clinical necessity (2–3 sentences)

When a denial occurs, schedule a peer-to-peer call with the plan's medical director promptly. Peer-to-peer reviews resolve many first-round denials and are typically faster than formal written appeals.

Step 3: Route Patients to the Correct Specialty Pharmacy

Once the PA is approved, ensure the prescription goes to the patient's plan-designated specialty pharmacy — not a retail location. Most retail pharmacies don't stock Praluent. Routing the prescription to the wrong pharmacy is a common cause of delay.

Common specialty pharmacies for PCSK9 inhibitors:

Accredo (Express Scripts preferred pharmacy for many commercial plans)

CVS Specialty (preferred for Aetna, many Blue Cross plans)

Walgreens Specialty (preferred for some UnitedHealthcare and other plans)

AllianceRx Walgreens (Blue Shield of California and others)

If a patient is unsure of their plan's preferred specialty pharmacy, have them call the member services number on the back of their insurance card. For patients who need help locating pharmacies that have Praluent in stock, medfinder calls pharmacies on their behalf to check availability — reducing the burden on your staff and the patient.

Step 4: Enroll Patients in Financial Assistance Programs Early

Cost is a major driver of non-adherence for PCSK9 inhibitors. Don't wait until the patient can't afford their first fill to discuss financial assistance. Discuss at the time of prescribing:

MyPRALUENT Copay Card (commercially insured patients): $35–$50/month copay, max $3,500/year savings. Call 1-844-772-5836 or visit praluent.com/starting-and-paying-for-praluent-rx.

MyPraluent Patient Assistance Program (uninsured or underinsured): Eligible patients may receive Praluent at no cost for up to 12 months. Income-based eligibility. Enroll via phone or online at the same number.

Medicare Extra Help / LIS (Medicare patients with limited income): Can reduce Part D premiums and copays. Helps patients who reach the Part D $2,100 annual out-of-pocket cap faster.

39,483+ patients found their medications in stock

39K+

Find Praluent In Stock Today →

Step 5: Advise Patients to Refill 7–10 Days Early

Praluent is injected every 2 or 4 weeks. Because specialty pharmacies may have 3–7 day shipping windows (and cold-chain delivery must maintain 36–46°F), patients who wait until the day before their injection is due may run out. Educate patients to contact their specialty pharmacy at least 7–10 days before their scheduled injection to ensure timely delivery.

Also advise patients that if a dose is missed: for every-2-week dosing, the missed dose can be given within 7 days of the scheduled date; if more than 7 days pass, skip it and resume at the next scheduled date. For every-4-week dosing, same rules apply — give within 7 days or skip to the next scheduled date.

Using medfinder to Support Your Patients

For patients who are struggling to find Praluent in stock after trying their specialty pharmacy — or who need help navigating pharmacy options — medfinder for providers calls pharmacies near the patient to check which ones have Praluent available and can fill the prescription. This reduces the burden on your staff and gets patients their medication faster.

For a broader overview of the Praluent access landscape, see our clinical briefing on Praluent access for providers.